Itraconazole oral solution and intravenous formulations: a review of pharmacokinetics and pharmacodynamics

被引:165
作者
Willems, L
van der Geest, R
de Beule, K
机构
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] Janssen Res Fdn, Beerse, Belgium
关键词
itraconazole; fungal infection; novel formulation; pharmacodynamics; pharmacokinetics;
D O I
10.1046/j.1365-2710.2001.00338.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Itraconazole is a triazole antifungal agent with a broad spectrum of activity. It is well tolerated and highly efficacious, particularly because its main metabolite, hydroxy-itraconazole, also has considerable antifungal activity. Two new formulations of itraconazole, an oral solution and an intravenous formulation, have recently been developed, which combine lipophilic itraconazole with cyclodextrin. These formulations have improved the solubility of itraconazole, leading to enhanced absorption and bioavailability compared with the original capsule formulation, without having an impact on the tolerability profile of itraconazole. The oral solution and intravenous formulations of itraconazole produce consistent plasma concentrations and are ideal for the treatment of systemic fungal infections in a wide range of patient populations. The additional flexibility offered by the different routes of administration means that itraconazole treatment can be specifically tailored for use in all patients, including children and those requiring intensive care.
引用
收藏
页码:159 / 169
页数:11
相关论文
共 67 条
[21]  
3.0.CO
[22]  
2-6
[23]   ITRACONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1989, 37 (03) :310-344
[24]   Randomized trial of itraconazole oral solution for oropharyngeal candidiasis in HIV/AIDS patients [J].
Graybill, JR ;
Vazquez, J ;
Darouiche, RO ;
Morhart, R ;
Greenspan, D ;
Tuazon, C ;
Wheat, LJ ;
Carey, J ;
Leviton, I ;
Hewitt, RG ;
MacGregor, RR ;
Valenti, W ;
Restrepo, M ;
Moskovitz, BL .
AMERICAN JOURNAL OF MEDICINE, 1998, 104 (01) :33-39
[25]   PHARMACOKINETICS OF ITRACONAZOLE FOLLOWING ORAL-ADMINISTRATION TO NORMAL VOLUNTEERS [J].
HARDIN, TC ;
GRAYBILL, JR ;
FETCHICK, R ;
WOESTENBORGHS, R ;
RINALDI, MG ;
KUHN, JG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1988, 32 (09) :1310-1313
[26]  
HAROUSSEAU JL, 1998, 38 INT C ANT AG CHEM
[27]   THE CLINICAL PHARMACOKINETICS OF ITRACONAZOLE - AN OVERVIEW [J].
HEYKANTS, J ;
VANPEER, A ;
VANDEVELDE, V ;
VANROOY, P ;
MEULDERMANS, W ;
LAVRIJSEN, K ;
WOESTENBORGHS, R ;
VANCUTSEM, J ;
CAUWENBERGH, G .
MYCOSES, 1989, 32 :67-87
[28]  
Hilfiker M L, 1995, Semin Pediatr Surg, V4, P239
[29]   EFFECT OF CYCLODEXTRIN ON THE PHARMACOLOGY OF ANTIFUNGAL ORAL AZOLES [J].
HOSTETLER, JS ;
HANSON, LH ;
STEVENS, DA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (02) :477-480
[30]   AZOLE DRUG-RESISTANCE IN YEASTS [J].
JOHNSON, EM ;
WARNOCK, DW .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (05) :751-755